EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Evotec SE
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 8, 2026
$1.42+0.04 (+2.90%)
Close on Oct 19, 2026
Evotec statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Evotec | Industry median |
|---|---|---|
| Market Cap | €451.08M | €878.09M |
| Enterprise Value | €114.06M | €706.41M |
| PS Ratio | 0.57 | 6.85 |
| PB Ratio | 0.55 | 0.94 |
| P/TBV Ratio | 0.88 | 1.22 |
Enterprise value
| Measure | Evotec | Industry median |
|---|---|---|
| EV / Sales | 0.14 | 3.86 |
| EV / EBITDA | 2.64 | 8.83 |
Income (trailing twelve months)
| Measure | Evotec | Industry median |
|---|---|---|
| Revenue | €788.37M | €465.66M |
| Gross Profit | €114.22M | €1.08B |
| Operating Income | -€56.22M | -€54.01M |
| Pretax Income | -€86.77M | -€47.40M |
| EBITDA | €43.26M | -€42.85M |
| EPS (Diluted) | -0.58 EUR | -0.55 EUR |
Margins
| Measure | Evotec | Industry median |
|---|---|---|
| Gross Margin | 14.5% | 42.5% |
| Operating Margin | -7.13% | -33.2% |
| Pretax Margin | -11.0% | -36.6% |
| EBITDA Margin | 5.49% | -28.6% |
| FCF Margin | -10.4% | -24.4% |
Returns
| Measure | Evotec | Industry median |
|---|---|---|
| Return on Invested Capital (ROIC) | -7.72% | 6.28% |
| Return on Capital Employed (ROCE) | -4.18% | -23.8% |
Growth
| Measure | Evotec | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -1.08% | -1.08% |
| Revenue Growth (3Y CAGR) | 1.61% | 1.61% |
| Revenue Growth (5Y CAGR) | 9.49% | 14.0% |
Balance sheet
| Measure | Evotec | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €418.52M | €199.29M |
| Total Debt | €81.50M | €184.06M |
| Net Cash (Debt) | €337.02M | €111.50M |
| Net Cash Per Share | 1.90 EUR | 1.53 EUR |
| Equity (Book Value) | €813.70M | €472.30M |
| Book Value Per Share | 4.58 EUR | 6.00 EUR |
| Tangible Book Value | €509.77M | €50.66M |
| Working Capital | €394.87M | €119.55M |
Financial position
| Measure | Evotec | Industry median |
|---|---|---|
| Current Ratio | 2.07 | 3.49 |
| Quick Ratio | 1.51 | 1.51 |
| Debt / Equity | 0.10 | |
| Debt / EBITDA | 1.88 | |
| Net Debt / EBITDA | -7.79 |
Cash flow (trailing twelve months)
| Measure | Evotec | Industry median |
|---|---|---|
| Operating Cash Flow | -€9.18M | -€42.16M |
| Capital Expenditures | -€72.54M | -€2.34M |
| Free Cash Flow | -€81.72M | -€52.90M |
| FCF Per Share | -0.46 EUR | -0.48 EUR |
Efficiency
| Measure | Evotec | Industry median |
|---|---|---|
| Asset Turnover | 0.43 | 0.31 |
| Inventory Turnover | 22.31 | 1.36 |
| Revenue Per Employee | €173.16K | €855.98K |
| Employee Count | 4,553 | 304 |
Dividends and yields
| Measure | Evotec | Industry median |
|---|---|---|
| FCF Yield | -18.1% | -13.6% |
| Buyback Yield | 0.34% | -11.4% |
| Shareholder Yield | 0.34% | -11.4% |
Shares
| Measure | Evotec | Industry median |
|---|---|---|
| Shares Outstanding | 177,779,000 | 99,540,150 |
| Shares Change (YoY) | 0.16% | 5.61% |
| Float | 147,366,000 | 78,574,400 |
| Shares Held by Insiders | 17.1% | 9.05% |
| Shares Held by Institutions | 1.82% | 13.8% |
Taxes
| Measure | Evotec | Industry median |
|---|---|---|
| Income Tax | €16.75M | €80.00K |
Scores
| Measure | Evotec | Industry median |
|---|---|---|
| Altman Z-Score | 0.30 | 1.13 |
Calculated by StockData from Evotec's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.